Metastatic prostate cancer prostate. Medical search. Frequent questions

So that's really giving us very little, even if we see a brief PSA [prostate-specific antigen] response, we're not going to meaningfully change the trajectory of the disease for the majority of patients. (medpagetoday.com)
While advanced prostate cancer was historically defined as distant metastatic disease, the current definition includes disease stages that range from recurrence of prostate-specific antigen (PSA) elevation after failure of local treatment to widespread metastasis. (medscape.com)
[ 6 ] Since the advent of prostate-specific antigen (PSA) screening, prostate cancer is being detected and treated earlier. (medscape.com)
The most common manifestation of advanced prostate cancer is a rising prostate-specific antigen (PSA) level after failure of initial local therapy. (medscape.com)
Docetaxel plus standard of care may be beneficial among patients with prostate cancer and low prostate-specific antigen levels who do not have any highly effective treatment options, says Anthony D' Amico, MD, PhD. (cancernetwork.com)
3 Functionally, sipuleucel-T consists of autologous peripheral blood mononuclear cells (including antigen-presenting cells) which are activated ex vivo with a recombinant fusion protein to target prostate cancer. (urotoday.com)
Patients with serum prostate-specific antigen (PSA) less than 5 or greater than 50 ng/mL, those with ECOG performance score greater than 2, visceral metastases, pathologic fractures, spinal cord compression, and use of systemic steroids within 28 days prior to enrollment were excluded. (urotoday.com)
Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). (snmjournals.org)
Prostate-specific antigen (PSA) was determined every 4 wk. (snmjournals.org)
Prostate-specific membrane antigen (PSMA) is a promising target for directing new therapies. (snmjournals.org)
Secondary endpoints included overall survival plus progression-free survival, prostate-specific antigen (PSA) response, tumor response, pain response, time to a symptomatic skeletal event, safety, health-related quality of life, and biomarker analysis. (ascopost.com)
Determine whether a decline in prostate-specific antigen (PSA) coincides with evidence of disease regression in these patients. (knowcancer.com)
Participants will undergo regular testing for signs of disease progression using computed tomography (CT) scans, magnetic resonance imaging (MRI), bone scans, and prostate-specific antigen (PSA) blood tests. (uclahealth.org)
New nomograms can predict survival outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177 prostate-specific membrane antigen ( 177- Lu-PSMA), according to a study published in The Lancet Oncology . (renalandurologynews.com)
The researchers also created a nomogram for prostate-specific antigen (PSA) progression-free survival (PFS). (renalandurologynews.com)
The drug candidate is a bi-specific T cell engager (TCE) which acts by targeting cells expressing prostate specific membrane antigen (PSMA) and T cells. (globaldata.com)
Last year, the FDA approved lutetium prostate-specific membrane antigen (PSMA), a promising new therapy for managing metastatic castrate-resistant prostate cancer. (clevelandclinic.org)
Lutetium-PSMA offers an option and is currently FDA-approved for people who have prostate cancer that has had progression on antigen receptor or a novel hormonal agent, as well as a taxane-based chemotherapy. (clevelandclinic.org)
Most cases of prostate cancer are detected after screening tests - typically blood tests for levels of prostate-specific antigen (PSA) - indicate unusual growth of prostate tissue due to prostate tumors or other conditions affecting the prostate. (wikipedia.org)
This is typically done through blood tests for levels of the protein prostate-specific antigen (PSA), which are elevated in those with enlarged prostates, whether due to prostate cancer or benign prostatic hyperplasia. (wikipedia.org)
Men are often diagnosed as the result of health screenings, such as a blood test for a substance called prostate specific antigen (PSA) or a medical exam called a digital rectal exam (DRE). (medlineplus.gov)
The guidelines differ in their recommendations regarding whether or not to provide routine prostate-specific antigen (PSA)-based prostate cancer screening, in what age groups and life expectancies, and at what intervals. (medscape.com)
The current recommendations of the AUA date from 2013 and update the Association's 2009 Best Practice Statement on Prostate-Specific Antigen (PSA). (medscape.com)

This clinical trial is studying a potential treatment for men with metastatic castration resistant prostate cancer. (facingourrisk.org)
First-line options for treating metastatic castration-resistant prostate cancer (mCRPC) were debated throughout the annual meeting of the American Urological Association (AUA). (medpagetoday.com)
The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while receiving the alternative inhibitor (abiraterone or enzalutamide) are unclear. (nih.gov)
Cabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who had been previously treated with docetaxel and the alternative androgen-signaling-targeted agent (abiraterone or enzalutamide). (nih.gov)
Treatment with Cabometyx plus Tecentriq improved progression-free survival for patients with metastatic castration-resistant prostate cancer. (curetoday.com)
The treatment combination of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) demonstrated significant improvements regarding survival without disease progression for patients with metastatic castration-resistant prostate cancer (mCRPC), according to preliminary results from a phase 3 trial. (curetoday.com)
Castration-resistant prostate cancer is when prostate cancer continues growing even though the amount of testosterone in the body reduces to very low levels, according to the National Cancer Institute. (curetoday.com)
Cabometryx) in combination with (Tecentriq) represents a potential new treatment modality for patients with metastatic castration-resistant prostate cancer, and we look forward to sharing the full data at a future medical meeting. (curetoday.com)
Patients with metastatic castration-resistant prostate cancer face a poor prognosis of less than two years, and many who progress on a novel hormonal therapy are seeking alternative treatment options to chemotherapy," said Dr. Vicki L. Goodman, executive vice president, product development and medical affairs and chief medical officer of Exelixis, in the press release. (curetoday.com)
Prior chemotherapy treatment for castration-sensitive or castration-resistant prostate cancer (docetaxel or cabazitaxel). (orlandohealth.com)
Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer. (cancernetwork.com)
1 With current treatment paradigms, nearly all patients who die of prostate cancer first receive androgen-deprivation therapy and then progress to castrate-resistant prostate cancer. (urotoday.com)
In patients with metastatic castrate-resistant prostate cancer (mCRPC) treatment options depend, in general terms, on three factors: whether the patient is symptomatic from their disease, the patient's performance status, and previous therapies which the patient may have received. (urotoday.com)
Published in 2010, the IMPACT study was the pivotal Phase III randomized controlled trial (RCT) which led to the approval of sipuleucel-T. 4 Men were enrolled if they had metastatic castrate-resistant prostate cancer and expected survival of at least six months. (urotoday.com)
TALAPRO-1: A Phase 2, Open-Label, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone. (pfizer.com)
Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer. (onclive.com)
Sabizabulin (VERU-111) was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer (mCRPC), according to phase 1b/2 clinical trial (NCT03752099) results presented at the 2021 ESMO Congress. (onclive.com)
Sabizabulin, an oral cytoskeleton disruptor, to treat men with metastatic castration resistant prostate cancer who failed an androgen receptor targeting agent. (onclive.com)
The Food and Drug Administration (FDA) has approved Lynparza ® (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adults with deleterious or suspected deleterious BRCA -mutated metastatic castration-resistant prostate cancer (mCRPC). (empr.com)
FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA -mutated metastatic castration-resistant prostate cancer. (empr.com)
Lynparza plus abiraterone approved in the US for the treatment of BRCA -mutated metastatic castration-resistant prostate cancer. (empr.com)
ERLEADA ® has shown a statistically significant improvement in OS with a consistent safety profile in both approved indications of mCSPC (TITAN) and non-metastatic castration-resistant prostate cancer or nmCRPC (SPARTAN). (jnj.com)
Despite recent approval of some novel drugs, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease and additional treatment options are still needed. (snmjournals.org)
Results of the study titled, " Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC) " indicated that pre-treatment, CTCs and lactate dehydrogenase (LDH), both alone and in combination, were prognostic biomarkers, while baseline prostate-specific antigen (PSA) was not. (jnj.com)
It was performed in 900 of the 1195 enrolled study patients with metastatic castration-resistant prostate cancer post-docetaxel being treated with either abiraterone acetate plus prednisone or placebo plus prednisone. (jnj.com)
In a single-institution phase I dose-expansion trial reported in The Lancet Oncology , Aggarwal et al found that a single dose of lutetium-177-PSMA-617 (LuPSMA) followed by pembrolizumab maintenance was associated with activity in patients with metastatic castration-resistant prostate cancer. (ascopost.com)
The investigators concluded, "A single priming dose of [LuPSMA] followed by pembrolizumab maintenance was safe and had encouraging preliminary activity in patients with metastatic castration-resistant prostate cancer. (ascopost.com)
Until now, the optimal sequencing of new agents available for metastatic castration-resistant prostate cancer has been unknown. (ascopost.com)
Docetaxel, enzalutamide, and abiraterone have all shown an overall survival benefit in metastatic castration-resistant prostate cancer, but a common clinical dilemma is how best to sequence these drugs. (ascopost.com)
Between 2015 and 2018 , the multicenter CARD trial enrolled men with metastatic castration-resistant prostate cancer that has progressed within 12 months of either enzalutamide or abiraterone therapy, before or after treatment with docetaxel. (ascopost.com)
The CARD study confirmed that cabazitaxel should be offered as third-line therapy after docetaxel and abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer who are fit for chemotherapy. (ascopost.com)
Belinostat is under clinical development by Acrotech Biopharma and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). (pharmaceutical-technology.com)
According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. (pharmaceutical-technology.com)
The study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor axis-targeted therapy (ARAT). (uclahealth.org)
Received 1 prior ARAT for metastatic or non-metastatic, castration-sensitive or castration-resistant prostate cancer. (uclahealth.org)
Patient and Methods: Retrospective analysis of trials using androgen receptor axis-targeted drugs for metastatic castration resistant prostate cancer patients (mCRPC). (lu.se)
JANX-007 is under development for the treatment of metastatic castration resistant prostate cancer (mCRPC). (globaldata.com)
Metastatic castration-resistant prostate cancer (mCRPC) is a type of cancer that is resistant to conventional prostate cancer treatments, such as androgen deprivation therapies (ADTs) and other chemotherapies. (oncologynurseadvisor.com)
Hence, understanding known mechanisms could be a start in coming up with novel therapies to combat resistant prostate cancer cells. (oncologynurseadvisor.com)
Q: Has there been progress in the treatment of metastatic, castration-resistant prostate cancer in recent years? (nejm.org)
Clinical progress in treating metastatic, castration-resistant prostate cancer during the past 7 years has been remarkable. (nejm.org)
Two new hormonal agents, abiraterone and enzalutamide, have had the largest effect on castration-resistant prostate cancer. (nejm.org)
Genomic aberrations in metastatic, castration-resistant prostate cancer may be similar to or distinct from genomic alterations in primary prostate tumors that have not been treated with androgen deprivation. (nejm.org)
PURPOSE: To investigate the role of patient-specific dosimetry as a predictive marker of survival and as a potential tool for individualised molecular radiotherapy treatment planning of bone metastases from castration-resistant prostate cancer, and to assess whether higher administered levels of activity are associated with a survival benefit. (mcmaster.ca)
In a recent podcast, a Taussig Cancer Center physician discusses treatment options, trials, and more for managing metastatic castrate-resistant prostate cancer. (clevelandclinic.org)
So, we know that this is a very effective and good option for men with castrate-resistant prostate cancer. (clevelandclinic.org)
Olaparib, a poly (ADP-ribose) polymerase inhibitor, has demonstrated an improvement in median progression-free survival (PFS) in select patients with metastatic castration-resistant prostate cancer (mCRPC). (bmj.com)
Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer. (bvsalud.org)
This most-advanced stage of the disease, called castration-resistant prostate cancer, is treated with continued hormone therapy alongside the chemotherapy drug docetaxel. (wikipedia.org)
The US Food and Drug Administration (FDA) has approved niraparib and abiraterone acetate (Akeega, Janssen Pharmaceuticals) to treat BRCA -positive, metastatic castration-resistant prostate cancer in adult patients with deleterious or suspected deleterious disease, as determined by an FDA-approved test. (medscape.com)
About 10% - 15% of patients who develop metastatic castration-resistant prostate cancer have BRCA gene alterations, and those patients are more likely to have aggressive disease, poor outcomes, and shorter survival. (medscape.com)

Fast Five Quiz: Advanced and Metastatic Prostate Cancer - Medscape - May 02, 2022. (medscape.com)

You might have hormone therapy for prostate cancer that has spread to another part of your body. (cancerresearchuk.org)
Remembering of course that we are going to try to intensify for all patients with metastatic hormone-sensitive disease, our patients are going to have been exposed to more than just ADT [androgen deprivation therapy] alone by the time they hit first-line mCRPC status, for most patients. (medpagetoday.com)
Tecentriq is an immune checkpoint inhibitor, which is a type of targeted therapy drug, and is also considered a monoclonal antibody that binds to the protein PD-L1 on the surface of certain cancer cells, preventing the cancer cells from suppressing the immune system, as noted from the National Cancer Institute. (curetoday.com)
Alicia Morgans, MD, MPH, mentions other factors clinicians need to consider before adding PARP inhibitors to metastatic prostate cancer therapy. (cancernetwork.com)
most men with prostate cancer, who require treatment with androgen deprivation therapy (ADT), will eventually become resistance to treatment leading to the development of metastatic disease. (malecare.org)
The aim of this review was to find out what the effect of adding abiraterone was, in men with prostate cancer, who were receiving and still responding to hormone therapy. (cochrane.org)
Systemic androgen deprivation therapy (ADT), also referred to as hormone therapy, has long been the primary treatment for metastatic prostate cancer. (cochrane.org)
RARITAN, N.J., February 8, 2021 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA ® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT. (jnj.com)
The TITAN final analysis further confirms that treatment with apalutamide can prolong overall survival and offer a clear long-term clinical benefit and established safety profile for patients with metastatic prostate cancer who are starting androgen deprivation therapy," said Dr. Kim Chi, Medical Oncologist at BC Cancer - Vancouver and principal investigator of the TITAN study. (jnj.com)
Another hematologic or solid tumor ≥ stage 1 malignancy that completed surgery, last dose of radiotherapy, or last dose of systemic anti-cancer therapy ≤ 2 years from first dose of study treatment. (uclahealth.org)
Participants who had curative therapy for non-melanomatous skin cancer or for localized malignancy are eligible. (uclahealth.org)
Metastatic prostate cancer can be broadly divided into two groups: disease that has not been treated with androgen deprivation and disease that is resistant to such therapy. (nejm.org)
Q: What new treatments may augment androgen-deprivation therapy alone for newly diagnosed metastatic prostate cancer? (nejm.org)
For men with an initial diagnosis of metastatic prostate cancer, continuous androgen-deprivation therapy represented the standard of care from 1941 until 2015, when two trials showed that androgen-deprivation therapy combined with six courses of docetaxel improved survival. (nejm.org)
The combination of androgen-deprivation therapy and abiraterone with prednisone represents a new standard of care for metastatic disease that is based on data from the CHAARTED and STAMPEDE trials. (nejm.org)
Though the effectiveness of abiraterone and that of docetaxel in prolonging survival appear to be equivalent, clear distinctions are noted in the duration of therapy used in previous trials for patients with an initial diagnosis of metastatic disease. (nejm.org)
Furthermore, despite a rationale for combination therapy (which is typically used for most cancers), no large, randomized trials testing combination therapy for advanced prostate cancer have been reported to date. (nejm.org)
Though newer studies indicate that a variety of potentially actionable genetic alterations can be detected in prostate cancer, no therapy targeting these alterations has yet been shown to have a clinical benefit. (nejm.org)
A new study has found that enzalutamide given with androgen deprivation therapy significantly reduced the risk of metastatic progression or death in men with metastatic hormone-sensitive prostate cancer versus placebo plus ADT, including patients with low-volume disease and/or prior docetaxel therapy. (targetedonc.com)
Patients had hormone-sensitive metastatic disease, either de novo or after recurrence following prior local therapy and an ECOG performance status of 0 or 1. (targetedonc.com)
In the enzalutamide group, 34 patients (5.9%) used concomitant antiandrogens as prostate cancer therapy during the study, while 43 patients (7.5%) in the placebo group did so. (targetedonc.com)
This phase II trial examines antiandrogen therapy interruptions in patients with hormone-sensitive prostate cancer that has spread to other places in the body (metastatic) responding exceptionally well to androgen receptor-pathway inhibitor therapy. (dana-farber.org)
Patients whose cancer is responding exceptionally well to this therapy may take a break from these medications according to their doctor's guidance. (dana-farber.org)
Prior local therapy for prostate cancer (either before or after diagnosis of metastatic disease) is permitted. (dana-farber.org)
You may also receive palliative treatments similar to those meant to get rid of the cancer, such as chemotherapy, surgery, or radiation therapy. (prostateprohelp.com)
Those whose cancer returns or has already spread beyond the prostate, are treated with hormone therapy that reduces levels of the male sex hormones that prostate cells need in order to survive. (wikipedia.org)
Withholding radical therapy for a large proportion of low-risk prostate cancer until signs of progress is a comparatively new strategy, named active surveillance. (cancercentrum.se)
The scientific hypothesis is that this alternative schedule for follow-up will identify the aggressive cancers earlier with less health-care resources and better quality of life for the patients, without increasing the total proportion of patients receiving radical therapy within 5 years. (cancercentrum.se)

Cite this: FDA OKs Combo Niraparib, Abiraterone Acetate for Prostate Cancer - Medscape - Aug 11, 2023. (medscape.com)

In conclusion, prostate cancer cells have resistance mechanisms to overcome cytotoxic therapies such as docetaxel and cabazitaxel. (oncologynurseadvisor.com)
Should men with newly diagnosed metastatic disease receive ADT combined with docetaxel or abiraterone acetate plus prednisone? (medscape.com)
Patients were also stratified by prior docetaxel chemotherapy for prostate cancer: 0 cycles, 1-5 cycles, or 6 cycles. (targetedonc.com)
The most common chemotherapy drug for prostate cancer is docetaxel , which is usually given with prednisone, a steroid medicine. (prostateprohelp.com)

You might have radiotherapy for prostate cancer that has spread to different parts of the body. (cancerresearchuk.org)
Radiotherapy uses high energy waves similar to x-rays to kill prostate cancer cells. (cancerresearchuk.org)
Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities. (cancernetwork.com)
Radiotherapy is a treatment that uses radioactivity to control cancer and relieve symptoms such as pain. (cancer.ie)
Radiotherapy is a standard treatment for localized prostate cancer, for palliative management of mCRPC, and even radiopharmaceuticals targeting the surrounding bone matrix instead of the tumor itself can improve survival ( 5 ). (snmjournals.org)
We sought to describe patterns of initial radiotherapy among non-metastatic prostate cancer (PC) patients by recurrence risk groups. (cdc.gov)

cancer (mCRPC). (facingourrisk.org)
Patients with mCRPC also tend to have a poor prognosis, in which survival is estimated to be one to two years, as reported in the journal Clinical Genitourinary Cancer . (curetoday.com)

LATITUDE was a multinational, multicenter, randomized, double-blind, placebo-controlled clinical trial that examined the use of abiraterone acetate 1,000 mg once daily in combination with prednisone 5 mg once daily, compared to placebos in patients with newly diagnosed, metastatic high-risk CSPC who had not received prior cytotoxic chemotherapy. (nursingcenter.com)
To assess the effects of early abiraterone acetate, in combination with systemic ADT, for newly diagnosed metastatic hormone-sensitive prostate cancer. (cochrane.org)
So now currently, we're testing in a clinical trial here at Cleveland Clinic for men that have newly diagnosed metastatic hormone sensitive prostate cancer that have PSMA avid disease on a PET scan. (clevelandclinic.org)
Today's topic is the management of newly diagnosed metastatic prostate cancer . (medscape.com)
For now, however, a man with newly diagnosed metastatic prostate cancer should be presented both sets of data and, along with his urologist, evaluate which of the two will be the best approach for him. (medscape.com)

Conversely, low-grade prostate tumors can also be biologically aggressive. (medscape.com)
Prostate cancer has a lower mutational burden, and the use of PD-1 inhibitors for prostate cancer remains experimental (though the activity of these agents may be higher in tumors with defective mismatch repair than in tumors with other genetic alterations). (nejm.org)
Screening can also involve a digital rectal exam to feel for prominent prostate tumors. (wikipedia.org)
Most prostate tumors remain small and cause no health problems. (wikipedia.org)
Prostate tumors were initially thought to be rare, with an 1893 report describing just 50 cases in the medical literature. (wikipedia.org)
As surgery became more common, prostate tumors were found in surgical specimens from prostates that had enlarged with age. (wikipedia.org)
Major work describing prostate tumors' unusual need for male sex hormones, and the subsequent development of hormone therapies for prostate cancer, earned Charles B. Huggins the 1966 Nobel Prize in Physiology or Medicine, and Andrzej W. Schally the 1977 Nobel Prize in Physiology or Medicine. (wikipedia.org)
Most cases of prostate cancer are diagnosed through screening tests, when tumors are too small to cause any symptoms. (wikipedia.org)
Prostate cancer screening searches for tumors in those without symptoms. (wikipedia.org)
Screening aims to separate men with high-risk cancers who would benefit from treatment, from those whose tumors are slow-growing and unlikely to impact health. (wikipedia.org)
Early-stage prostate cancer can usually be treated successfully, and some older men have prostate tumors that grow so slowly that they may never cause health problems during their lifetime, even without treatment. (medlineplus.gov)
Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers . (medlineplus.gov)
Most extradural tumors are metastatic. (msdmanuals.com)

In a recent episode of Cleveland Clinic's Cancer Advances podcast , Dr. Wee discusses standard of care for metastatic prostate cancer and the potential role of Lutetium-PSMA. (clevelandclinic.org)

The 5-year relative survival rate for localized and regional prostate cancer is 100%, compared with 34.1% for metastatic cases. (medscape.com)
Preliminary findings from the trial established that the use of Cabometyx combined with Tecentriq has demonstrated a significant improvement in progression-free survival (PFS), defined as the period during and after treatment of cancer when the disease does not worsen, during the primary analysis. (curetoday.com)
The primary endpoint was radiological progression free survival (rPFS), defined as the time from randomization to radiological progression, as assessed by investigator per RECIST 1.1 and Prostate Cancer Working Group (PCWG3) (bone) criteria. (empr.com)
It probably improves cancer-specific survival and reduces disease progression. (cochrane.org)
The certainty of the evidence was moderate for quality of life, cancer-specific survival (time to death from prostate cancer), time to disease progression, and discontinued treatment due to adverse events. (cochrane.org)
Initial results from the TITAN study presented at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) and simultaneously published in The New England Journal of Medicine showed the addition of ERLEADA ® (apalutamide) to ADT compared to placebo plus ADT significantly improved the dual primary endpoints of OS and radiographic progression-free survival (rPFS) in patients with mCSPC. (jnj.com)
Third-line treatment with cabazitaxel extended progression-free survival and overall survival in men with metastatic castration-resis tant prostate cancer in the CARD trial. (ascopost.com)
Introduction: Radiographic progression-free survival (rPFS) by Prostate Cancer Working Group (PCWG) criteria is a radiographic endpoint. (lu.se)
Here, we report that high expression of CRIPTO correlates with poor survival in stratified risk groups of prostate cancer (PCa) patients. (eur.nl)
10.1056/NEJMra1701695/T1) Practice-Changing Trials of Treatments for Metastatic Prostate Cancer That Improve Survival. (nejm.org)
Survival for prostate cancer is generally good, particularly if you are diagnosed early. (healthyprostateclub.com)
Find the survival rates for prostate cancer here. (healthyprostateclub.com)
The earlier the detection of prostate cancer, the better the patients chance of survival is. (healthyprostateclub.com)
If prostate cancer is diagnosed at an early stage, the chances of survival are generally good. (prostateprohelp.com)
Using this method, we could reveal that unedited, but not edited, miR-379 was frequently downregulated in prostate cancer patients with metastasis, treatment resistance, and shorter overall survival. (lu.se)
Despite the apparent survival advantage of early diagnosis conferred by PSA screening, a 2008 US Preventive Services Task Force statement recommended against screening for prostate cancer in men aged 75 years or older. (medscape.com)
Two recent papers, one a systematic review of literature on COVID-19 therapies and anticancer drugs and the other a study of the clinical characteristics of patients with metastatic prostate cancer who are infected with COVID-19, are examples of this international effort to investigate the effects of COVID-19 on cancer mortality and survival. (who.int)
In addition, SAMS will evaluate prognostic factors, criteria for intervention and the effects of 5-alpha-reductase inhibitors, the outcome after treatment with curative intent, time to symptoms and metastases from prostate cancer, prostate cancer specific survival, and overall survival. (cancercentrum.se)

The FDA has approved a new indication for abiraterone acetate in combination with prednisone for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer (CSPC). (nursingcenter.com)
The approval is based on phase III data from the pivotal LATITUDE clinical trial, which showed abiraterone acetate in combination with prednisone reduced the risk of death by 38 percent compared to placebos in patients with metastatic high-risk CSPC. (nursingcenter.com)
With [this] approval, abiraterone acetate plus prednisone could become a standard of care for patients with metastatic high-risk castration-sensitive prostate cancer. (nursingcenter.com)
Abiraterone acetate is a medication that blocks the effect of male sex hormones, and thereby, slows down prostate cancer growth. (cochrane.org)
Recent studies have looked at whether drugs that block the growth of prostate cancer cells, such as abiraterone acetate, can improve how men do. (cochrane.org)
We included randomized trials, in which men diagnosed with hormone-sensitive prostate cancer were administered abiraterone acetate and prednisolone with ADT or ADT alone. (cochrane.org)
Yet again, this represents a possible paradigm shift in the treatment of metastatic prostate cancer , because these data show that adding early use of abiraterone acetate with prednisone to ADT can help patients. (medscape.com)

Cabometyx - a tyrosine kinase inhibitor which prevents cancer cell growth - is an oral tablet that has been approved in the United States to treat several diseases, including advanced renal cell carcinoma, locally advanced or metastatic differentiated thyroid cancer and hepatocellular carcinoma for patients who have previously been treated with Nexavar (sorafenib). (curetoday.com)
Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by the U.S. Food and Drug Administration for locally advanced or metastatic urothelial cancer and locally advanced, unresectable stage 3 non-small cell lung cancer. (bmj.com)

Symptoms of metastatic prostate cancer include bone pain, problems passing urine and tiredness. (cancerresearchuk.org)
And if a patient has bone-only metastatic disease and has some symptomatology, even if that's just an anemia or some mild fatigue, then radium can be an option there as well. (medpagetoday.com)
They can shrink any areas of cancer in the bone by killing the cancer cells, which can relieve pain and improve your overall prognosis. (cancer.ie)
Metastatic prostate cancer can cause issues such as urinary problems, bone pain and weakened bones. (cancer.ie)
We look forward to further investigating the potential predictive benefit of CTCs in metastatic prostate cancer clinical trials as there are limited ways of assessing therapeutic benefit in this disease, especially when it has metastasized to the bone. (jnj.com)
Participants must have ≥ 1 metastatic lesion that is present on magnetic resonance imaging (MRI), computed tomography (CT), or bone scan obtained ≤ 28 days prior to initiation of study treatment. (uclahealth.org)
Predictors selected for the OS model were time since diagnosis, chemotherapy status, baseline hemoglobin, bone involvement, liver involvement, number of metastatic lesions, and mean tumor standardized uptake value (SUV mean ). (renalandurologynews.com)
Prostate cancer bone metastasis is still not fully understood, and increased knowledge could aid in the development of better treatment options for patients in the future. (lu.se)
Using cell culture, animal and patient studies, we investigated the biological role of microRNA-96 (miR-96) and microRNA-379 (miR-379) in prostate cancer bone metastasis. (lu.se)
In Paper II, we performed an in vivo anti-miRNA library screen, and identified miR-379 as a suppressor of prostate cancer bone metastasis. (lu.se)
In bone metastasis samples from prostate cancer patients, miR-379 was frequently downregulated. (lu.se)
Overall, this thesis reports multiple findings and tools that can help us better understand the process of prostate cancer bone metastasis and the role that miRNAs play in this process. (lu.se)
Metastases can damage the bones around them, and around a quarter of those with metastatic prostate cancer develop a bone fracture. (wikipedia.org)

At your initial screening visit, the study team will ask questions about your cancer diagnosis and medical history, perform a physical exam, laboratory tests, CT/MRI scans and electrocardiogram (ECG), and possibly take a biopsy of your tumor. (facingourrisk.org)
The most important and established prognosticators for prostate carcinoma include the Gleason grade, the extent of tumor volume, and the presence of capsular penetration or margin positivity at the time of prostatectomy. (medscape.com)
Chicago, IL (June 4, 2011) -- Data presented at the 47th American Society of Clinical Oncology (ASCO) annual meeting demonstrate the potential of circulating tumor cells (CTC) as a biomarker for metastatic prostate cancer clinical trials. (jnj.com)
75,76 Tumor necrosis factor (TNF)-α inhibits apoptosis by activating NF-κB and its downstream pathway, including IL6 and IL8, in androgen-independent prostate cancer cells, whereas it promotes apoptosis in androgen-dependent cancer cells. (oncologynurseadvisor.com)
The presence of high expressing epithelial cell adhesion molecule (EpCAM high ) circulating tumor cells (CTC) enumerated by CellSearch ® in blood of cancer patients is strongly associated with poor prognosis. (oncotarget.com)
If cancer is present, the pathologist assigns a Gleason score of 6 to 10, with higher scores representing a more dangerous tumor. (wikipedia.org)
This halts tumor growth for a while, but eventually cancer cells grow resistant to this treatment. (wikipedia.org)
As a tumor grows beyond the prostate, it can damage nearby organs causing erectile dysfunction, blood in the urine or semen, or trouble urinating - often frequent urination and slow or weak urine stream. (wikipedia.org)
In this disorder, certain cells in the prostate become abnormal, multiply without control or order, and form a tumor. (medlineplus.gov)

A study at the Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio tried to identify predictors of clinical disease progression in patients with prostate cancer who were receiving ADT. (malecare.org)
Thus, advanced genetics and immunology, two major drivers of progress in oncology, are not routinely incorporated into the care of patients with prostate cancer. (nejm.org)
Therefore, this new agent "brings an important treatment option to patients with prostate cancer as they consider their road ahead," said Shelby Moneer , vice president of patient programs and education at ZERO Prostate Cancer. (medscape.com)
The study of the clinical characteristics of patients with metastatic prostate cancer who are infected with COVID-19 provides observations from a small sample of patients with prostate cancer in South Italy that seem to align with results from other regions of the world in relation to COVID-19 treatment, hormone levels, and options for the management of patients with prostate cancer who are positive for COVID-19. (who.int)

High-grade prostate cancer, particularly the percentage presence of Gleason grades 4 and 5, is associated with adverse pathologic findings and disease progression. (medscape.com)
[ 5 ] Prostate cancer tends to not only be more aggressive and progressive in Black men, leading to advanced disease, but to also be of a higher grade at diagnosis. (medscape.com)
If I have a patient who has disease progression and maybe some clinical symptoms, but has a BRCA2 mutation, then I might feel more confident that olaparib or even rucaparib will be able to get that cancer under control maybe more quickly than if that patient had an ATM or CDK12 mutation. (cancernetwork.com)
Men who develop metastatic castrate-resistant disease have a very poor prognosis. (malecare.org)
One hundred ninety-one men (4.8%) progressed to metastatic disease at a median of 18 months from the initiation of ADT (range, 1-139 months). (malecare.org)
More than 15% of men diagnosed with prostate cancer present with disease that has spread beyond the prostate. (cochrane.org)
Medical records were abstracted for a sample of 9017 PC cases diagnosed in 2004 as a part of the Center for Disease Control and Prevention's Prostate and Breast Patterns of Care Study in seven states. (cdc.gov)
They found 11.8 percent of men with metastatic disease had a DNA-repair gene mutation. (michiganmedicine.org)
You wouldn't screen patients with clinically localized disease, but for metastatic prostate cancer, it makes sense that they would be screened. (michiganmedicine.org)
These are patients with metastatic disease who don't have a good prognosis. (michiganmedicine.org)
This review summarizes the current data on the role of several candidate biomarkers that have been evaluated in the advanced/metastatic disease setting. (northwestern.edu)
Must have remained on testosterone suppression for metastatic disease continuously (without treatment breaks) for 540-750 days (approximately 18 to 24 months) from time of first dose of LHRH agonist or antagonist by time of registration. (dana-farber.org)
If the cancer cannot be cured or controlled, the disease may be called advanced or terminal. (prostateprohelp.com)
Most prostate cancer-related deaths are due to advanced disease, which results from any combination of lymphatic, blood, or contiguous local spread. (medscape.com)
nonetheless, advanced disease is comparably less common, because more early stage cancer is being discovered. (medscape.com)
Each year 1.2 million cases of prostate cancer are diagnosed, and 350,000 die of the disease, making it the second-leading cause of cancer and cancer death in men. (wikipedia.org)
One in eight men is diagnosed with prostate cancer in his lifetime, while one in forty dies of the disease. (wikipedia.org)
Prostate cancer is a common disease that affects men, usually in middle age or later. (medlineplus.gov)
The signs and symptoms of metastatic cancer depend on where the disease has spread. (medlineplus.gov)
In the United States, African Americans have a higher risk of developing prostate cancer than do men of other ethnic backgrounds, and they also have a higher risk of dying from the disease. (medlineplus.gov)
Autopsy studies have found that the majority of men have some evidence of prostate cancer at death, even though they did not die from the disease. (cdc.gov)
The NCCN recommends performing a baseline history (including family history, medications, and any history of prostate screening and disease) and physical examination. (medscape.com)
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. (bvsalud.org)
The International Agency for Research on Cancer (IARC) is working with partners to assess the impact of coronavirus disease (COVID-19) on cancer and cancer prevention. (who.int)

And they may of course come in through a non-metastatic CRPC pathway as well, again with intensified treatment. (medpagetoday.com)
More than 330,000 patients worldwide, including 113,000 in the U.S., have received treatment with it, and it was the number one prescribed oral medication in the U.S. for patients with metastatic CRPC in 2016. (nursingcenter.com)

They evaluated 13,740 men with biopsy-confirmed prostate cancer who were enrolled in the Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE) database from 1995 to 2007. (malecare.org)
A pathologist determines your Gleason score by looking at a biopsy of your prostate tissue under a microscope. (healthyprostateclub.com)
A definitive diagnosis requires a biopsy of the prostate. (wikipedia.org)
Another consideration is that a positive PSA test might lead to decisions to have another test, a biopsy, to check to see if the PSA test is high because of prostate cancer. (cdc.gov)
A biopsy involves removing a small piece of tissue from the prostate and looking at it under a microscope. (cdc.gov)
NCCN panel members were divided on the question of PSA thresholds that would prompt prostate biopsy: options include 2.5 ng/mL, 3 ng/mL, or considering the PSA level in the context of other risk factors rather than using a specific PSA cutoff. (medscape.com)

Treatment for metastatic or advanced prostate cancer can help to reduce symptoms, make you feel better and help you to live longer. (cancerresearchuk.org)
This section is about treatment for prostate cancer that has spread to another part of the body. (cancerresearchuk.org)
We have separate information about treatment for cancer that hasn't spread to another part of the body. (cancerresearchuk.org)
Chemotherapy is a common treatment for metastatic prostate cancer. (cancerresearchuk.org)
Find out about the latest research into the treatment of prostate cancer. (cancerresearchuk.org)
These positive findings from CONTACT-02 are highly encouraging given the need for additional, non-cytotoxic or non-chemotherapeutic treatment options for this patient population," Dr. Neeraj Agarwal, professor and presidential endowed chair of cancer research at Huntsman Cancer Institute, University of Utah and the global lead investigator of the trial, said in the press release. (curetoday.com)
Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests. (cancernetwork.com)
Preventing or delaying radiographic progression is an important clinical endpoint in assessing cancer treatment and is very important to patients, their caregivers and their families," said Andrew Armstrong, MD, ScM, Duke Cancer Institute, Durham, N.C. and an investigator in the trial. (empr.com)
Additionally, Lynparza is indicated for the treatment of ovarian cancer , breast cancer , and pancreatic cancer . (empr.com)
Another 15% to 30% of men who undergo primary treatment will experience a return of their cancer. (cochrane.org)
In one of the studies, most of the included men had high risk prostate cancer, and had previously undergone local treatment. (cochrane.org)
In the other study, most men had not had previous treatment to their prostate. (cochrane.org)
An independent study investigating the in vitro diagnostic use of CTC testing found that the number of CTCs in the blood may help physicians more reliably assess treatment benefit for patients with metastatic breast cancer. (jnj.com)
Does the use of advanced genomic analysis of prostate cancer specimens improve treatment decisions for patients? (nejm.org)
Q: What are some of the unmet challenges regarding the treatment of metastatic prostate cancer? (nejm.org)
Testing men with metastatic prostate cancer for inherited genetic mutations could help guide treatment choices and alert family members to their potential cancer risk. (michiganmedicine.org)
Cite this: New Data Change Metastatic Prostate Cancer Treatment Paradigm - Medscape - Aug 14, 2017. (medscape.com)
The usual treatment for patients with metastatic prostate cancer is to receive hormonal medications including a medication to decrease testosterone levels in the body and a potent oral hormonal medication to block growth signals from male hormones (like testosterone) in the cancer cells. (dana-farber.org)
Cancer and its treatment cause physical symptoms and side effects, as well as emotional, social, and financial effects. (prostateprohelp.com)
People who receive palliative care along with treatment for the cancer often have less severe symptoms, better quality of life, and report that they are more satisfied with treatment. (prostateprohelp.com)
This treatment is an option for curing prostate cancer that has not spread beyond the prostate or has not spread very far. (prostateprohelp.com)
It's possible that prostate cancer can come back again after treatment. (prostateprohelp.com)
Your doctor should be able to explain the risk of your cancer coming back after treatment, based on things like your PSA level and the stage of your cancer. (prostateprohelp.com)
Continuous advances have provided a new understanding of the diagnosis, staging, and treatment of metastatic and advanced prostate cancer. (medscape.com)
Accumulating evidence is showing that, owing to early diagnosis and treatment, the mortality rate associated with prostate cancer has declined since the 1970s. (medscape.com)
Finding prostate cancer early may make treatment easier, and even help save our life. (cdc.gov)
Making matters worse, prostate cancer treatment can have serious side effects. (cdc.gov)
Hopefully, SAMS will increase our knowledge on active surveillance for low-risk prostate cancer, so that more patients with aggressive cancer will receive curative treatment and fewer patients will receive un-necessary treatment for indolent tumours and thereby maintain their quality of life better. (cancercentrum.se)

Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology , is one of the study's authors and the principal investigator on the Stand Up to Cancer/Prostate Cancer Foundation Dream Team that led this study. (michiganmedicine.org)
As a physician, identifying patients with a worse prognosis is a priority, especially those whose cancers have a BRCA mutation," principal investigator Kim Chi, MD, stated in the Janssen press release . (medscape.com)

CRIPTO and its signaling partner glucose-regulated protein 78 (GRP78) are highly expressed in PCa metastases and display higher levels in the metastatic ALDHhigh sub-population of PC-3M-Pro4Luc2 PCa cells compared with non-metastatic ALDHlow. (eur.nl)

Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. (cdc.gov)

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) requires systematic treatments. (physiciansweekly.com)
Advice and information on treatments and activities that go along with standard cancer medical treatments. (cancer.ie)
Stand Up To Cancer works relentlessly to offer the newest, most effective, and most promising cancer treatments to patients quickly by bringing together the best minds to collaborate, innovate, and share cancer research. (standuptocancer.org)
Thanks to the support of our dedicated partners and the entertainment community, SU2C is able to bring widespread attention to cancer research and treatments. (standuptocancer.org)
Stand Up To Cancer was created to accelerate groundbreaking cancer research that will get promising new cancer treatments to patients quickly. (standuptocancer.org)
There are a couple of other different treatments [after frontline therapies], but once we get past one or two treatments, the options become more and more limited," says Christopher Wee, MD , a physician in the Genitourinary Medical Oncology Program at Taussig Cancer Center. (clevelandclinic.org)
Since 1947, Dana-Farber's sole focus has been to provide expert cancer care and groundbreaking treatments for adult and pediatric patients. (dana-farber.org)
It is an important part of your care that is included along with treatments intended to slow, stop, or eliminate the cancer. (prostateprohelp.com)
The stage of the cancer will determine which types of treatments will be necessary. (prostateprohelp.com)
If a screening test finds a slow-growing cancer, some men may decide too early to get unnecessary cancer tests and treatments. (cdc.gov)

People with Metastatic Hormone Sensitive Prostate Cancer are asked to participate in a research study being conducted by Montefiore Medical Center. (brany.com)

OBJECTIVES: I. Determine the effectiveness and toxicity of green tea extract in patients with androgen-independent metastatic prostate cancer. (knowcancer.com)

All patients had biopsies of metastatic lesions with an evaluation for both germline and somatic mutations. (bmj.com)

Browse through our list of patient and caregiver resources to help you throughout your cancer journey, and learn more about clinical trials. (standuptocancer.org)
Search clinical trials for adult and pediatric cancers and blood disorders offered through Dana-Farber and our clinical partners. (dana-farber.org)

Histologically or pathologically confirmed prostate adenocarcinoma without predominant small cell component. (orlandohealth.com)
Histologically confirmed adenocarcinoma of the prostate without evidence of neuroendocrine differentiation, signet cell, or small cell features. (uclahealth.org)

But 71 percent of the men with DNA-repair mutations had a relative with cancer other than prostate, including breast, ovarian, leukemia, lymphoma, pancreatic or other gastrointestinal cancers. (michiganmedicine.org)

This evaluation uses new cost-effectiveness estimates to update olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NICE technology appraisal guidance TA831). (bvsalud.org)
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults. (bvsalud.org)

The prognosis for prostate cancer, as with any cancer, depends on how advanced the cancer has become, according to established stage designations. (healthyprostateclub.com)
Prostate cancer prognosis depends on how far the cancer has spread at diagnosis. (wikipedia.org)

Radioactive injections can help with symptoms of prostate cancer that has spread to the bones. (cancer.ie)
Other symptoms of advanced and metastatic prostate cancer may include fatigue, urinary symptoms, and sexual function symptoms. (medscape.com)
Early prostate cancer usually causes no symptoms. (wikipedia.org)
Early prostate cancer usually does not cause pain, and most affected men exhibit no noticeable symptoms. (medlineplus.gov)
Having one or more of these symptoms does not necessarily mean that a man has prostate cancer. (medlineplus.gov)
In addition, studies indicate that many older men have undiagnosed prostate cancer that is non-aggressive and unlikely to cause symptoms or affect their lifespan. (medlineplus.gov)
With all these varying circumstances, it's helpful for us to become aware of physical changes with our bodies-changes that may signal symptoms of prostate cancer. (cdc.gov)

Those with mutations were not more likely to have a family history of prostate cancer. (michiganmedicine.org)
As a result of its genetic linkage, prostate cancer is more common in males with a strong family history of prostate cancer. (medscape.com)
Specifically, the USPSTF lists African American men and men with a family history of prostate cancer as higher risk groups. (cdc.gov)

A new study published in the New England Journal of Medicine found that inherited genetic mutations were much more common in men with metastatic prostate cancer than in men with early stage prostate cancer. (michiganmedicine.org)
Researchers performed genetic sequencing on 692 metastatic prostate cancer samples to identify mutations that disrupt the function of genes involved in repairing DNA damage. (michiganmedicine.org)
Testing among men with early stage prostate cancer found only 4.6 percent had genetic mutations. (michiganmedicine.org)
Previous studies have shown metastatic prostate cancer with DNA-repair gene mutations have responded to a class of drugs known as PARP inhibitors and to platinum-based chemotherapy. (michiganmedicine.org)
Second, identifying these mutations could trigger family members to seek genetic testing and potentially discover if they are at high risk of cancer. (michiganmedicine.org)
Cancers occur when genetic variants (also known as mutations) build up in critical genes, specifically those that control cell growth and division or the repair of damaged DNA. (medlineplus.gov)
Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development. (cdc.gov)
Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. (cdc.gov)
Germline BLM mutations and metastatic prostate cancer. (cdc.gov)

It is found in most prostate cancers ( 1 ), and its overexpression correlates with traditional adverse prognostic factors ( 2 ). (snmjournals.org)

In most cases of prostate cancer, these genetic changes are acquired during a man's lifetime and are present only in certain cells in the prostate. (medlineplus.gov)

The clinician should then discuss of the risks and benefits of a baseline PSA test with the patient, and consider a baseline DRE to identify high-risk cancers associated with a seemingly normal PSA. (medscape.com)

Novel forms of immunotherapy, especially PD-1 inhibitors, are active in a variety of cancers, especially those with high mutational frequencies. (nejm.org)
That's essentially why PARP inhibitors work preferentially in cancer cells and not normal cells. (michiganmedicine.org)
Background Checkpoint inhibitors have not been effective for prostate cancer as single agents. (bmj.com)

Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer. (cdc.gov)

The risk of developing prostate cancer increases with age, and the average age of diagnosis is 67. (wikipedia.org)
Less commonly, genetic changes present in essentially all of the body's cells increase the risk of developing prostate cancer. (medlineplus.gov)
Men with variants in these genes have a high risk of developing prostate cancer and, in some cases, other cancers during their lifetimes. (medlineplus.gov)

With prostate cancer confirmed as the second most commonly occurring cancer in men globally, the need for innovative new therapies is extensive, especially for those whose cancer has progressed to the metastatic castration-resistant form," said Howard Mayer, executive vice president and head of research and development at Ipsen, in the press release. (curetoday.com)

Anatomy13

Organisms4

Diseases34

Chemicals and Drugs76

Analytical, Diagnostic and Therapeutic Techniques and Equipment78

Psychiatry and Psychology2

Phenomena and Processes45

Disciplines and Occupations2

Anthropology, Education, Sociology and Social Phenomena2

Humanities1

Information Science10

Named Groups4

Health Care35

Geographicals2

Antigen23

Resistant Prostate Cancer51

20221

Therapy28

20231

Docetaxel4

Radiotherapy6

MCRPC2

Newly diagnosed5

Tumors13

Standard of care for metasta1

Survival18

Abiraterone7

Locally advanced or metastatic2

Bone13

Tumor9

Patients with prostate4

Disease24

CRPC2

Biopsy6

Treatment28

Principal investigator2

Metastases1

Colorectal cancer1

Treatments10

Sensitive Prostate Cancer1

Androgen-independent1

Lesions1

Clinical trials2

Histologically2

Pancreatic1

Hormone2

Prognosis2

Symptoms7

Family history of prostate cancer3

Mutations9

Prognostic1

Cases of prostate cancer1

High-risk cancers1

Inhibitors3

Breast cancer1

Risk of developi3

Therapies1